Details for New Drug Application (NDA): 215572
✉ Email this page to a colleague
NDA 215572 describes SPIRONOLACTONE, which is a drug marketed by Amneal, Accord Hlthcare, Actavis Elizabeth, Amneal Pharms, Ascot, Aurobindo Pharma, Chartwell Rx, Ivax Pharms, Jubilant Generics, Lederle, Mutual Pharm, Mylan, Norvium Bioscience, Oxford Pharms, Purepac Pharm, Sun Pharm Industries, Superpharm, Upsher Smith, Vangard, Warner Chilcott, Watson Labs, Zydus Pharms, Parke Davis, and Usl Pharma, and is included in forty-one NDAs. It is available from forty-one suppliers. Additional details are available on the SPIRONOLACTONE profile page.
The generic ingredient in SPIRONOLACTONE is hydrochlorothiazide; spironolactone. There are thirty-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; spironolactone profile page.
The generic ingredient in SPIRONOLACTONE is hydrochlorothiazide; spironolactone. There are thirty-two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; spironolactone profile page.
Summary for 215572
| Tradename: | SPIRONOLACTONE |
| Applicant: | Amneal |
| Ingredient: | spironolactone |
| Patents: | 0 |
Pharmacology for NDA: 215572
| Mechanism of Action | Aldosterone Antagonists |
Medical Subject Heading (MeSH) Categories for 215572
Suppliers and Packaging for NDA: 215572
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SPIRONOLACTONE | spironolactone | SUSPENSION;ORAL | 215572 | ANDA | ATLANTIC BIOLOGICALS CORP. | 17856-2028 | 17856-2028-3 | 60 SYRINGE in 1 PACKAGE (17856-2028-3) / 10 SYRINGE in 1 SYRINGE (17856-2028-2) / 2.5 mL in 1 SYRINGE (17856-2028-1) |
| SPIRONOLACTONE | spironolactone | SUSPENSION;ORAL | 215572 | ANDA | Amneal Pharmaceuticals NY LLC | 69238-2027 | 69238-2027-2 | 473 mL in 1 BOTTLE (69238-2027-2) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION;ORAL | Strength | 25MG/5ML | ||||
| Approval Date: | Sep 5, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
